Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Teriflunomide · Aubagio

Small molecule · Inhibitor of dihydroorotate dehydrogenase (DHODH) · developed by Sanofi Aventis Us

Approved FDA, Sep 2012
SNY Developer
1 Registered trials

What is Teriflunomide?

Teriflunomide is an oral immunomodulatory small molecule that inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme in de novo pyrimidine synthesis, which may reduce the number of activated lymphocytes in the central nervous system. It is studied in multiple sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Aubagio
Drug type
Small molecule
Targets
dihydroorotate dehydrogenase (DHODH)
Mechanism
Inhibitor of dihydroorotate dehydrogenase (DHODH)
Pathways
de novo pyrimidine synthesis, lymphocyte activation
Therapy area
Immunology, Neurology
Developer
Sanofi Aventis Us (SNY)
FDA status
Approved as Aubagio (September 12, 2012), NDA202992 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07930624 Phase 3 Multiple Sclerosis Not yet recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Sclerosis

Other drugs acting on DHODH

More from Sanofi Aventis Us

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Teriflunomide

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.